IRulya Therapeutics Inc. SEC filings

Filings

Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.

1. ROUTINESCHEDULE 13GIRulya Therapeutics Inc.QNCX4d

   2 13G filings

   Ownership stake disclosure by Foresite Capital Fund VI LP

   Show all 2

   • SCHEDULE 13GOwnership stake disclosure4d
   • SCHEDULE 13GOwnership stake disclosure4d

   Foresite Capital Fund VI LP, filed by

2. MAJOR8-KQuince Therapeutics, Inc.QNCXOct 9

   Quince Therapeutics names new CEO

   • Dirk Thye resigned as CEO and director on Oct 8, 2026
   • Brigette Roberts appointed CEO effective Oct 8, 2026
   • Company to change name to IRulya Therapeutics on Oct 9, 2026
3. ROUTINES-8Quince Therapeutics, Inc.QNCXOct 8

   Quince Therapeutics files S-8 form

   • Filed on 2026-10-08
   • Registers 2,199,717 shares under 2026 Equity Incentive Plan
   • Includes 142,045 shares for 2026 Employee Stock Purchase Plan
4. ROUTINE8-KQuince Therapeutics, Inc.QNCXOct 8

   Quince Therapeutics approves new stock plans

   • Approved 2026 Equity Incentive Plan with 821,872 initial shares
   • Approved 2026 Employee Stock Purchase Plan with 142,045 initial shares
   • Increased authorized common stock from 250M to 275M shares
5. ROUTINEDEFA14AQuince Therapeutics, Inc.QNCXOct 2

   Quince Therapeutics, Inc. announces board changes

   • Resigning Directors: June Bray, David Lamond, Christopher Senner
   • Incoming Directors: Catherine Bonuccelli, Leone Patterson, James Valentine, Drayton Wise
   • Board changes contingent on stockholder approvals
6. MAJOR8-KQuince Therapeutics, Inc.QNCXOct 2

   Quince Therapeutics, Inc. announces director changes

   • Resigning Directors: June Bray, David Lamond, Christopher Senner
   • Incoming Directors: Catherine Bonuccelli, Leone Patterson, James Valentine, Drayton Wise
7. ROUTINE8-KQuince Therapeutics, Inc.QNCXSep 14

   Current report

8. ROUTINE8-KQuince Therapeutics, Inc.QNCXSep 4

   Current report

9. ROUTINE8-KQuince Therapeutics, Inc.QNCXAug 27

   Current report

10. ROUTINEDEF 14AQuince Therapeutics, Inc.QNCXAug 25

    Proxy statement

11. ROUTINEEFFECTQuince Therapeutics, Inc.QNCXAug 25

    Registration declared effective

12. ROUTINE8-KQuince Therapeutics, Inc.QNCXAug 17

    Current report

13. ROUTINESCHEDULE 13GQuince Therapeutics, Inc.QNCXAug 14

    Ownership stake disclosure by Ikarian Capital, LLC

    Ikarian Capital, LLC, filed by

14. ROUTINESCHEDULE 13G/AQuince Therapeutics, Inc.QNCXAug 14

    Ownership stake disclosure by Nantahala Capital Management, LLC (amended)

    Nantahala Capital Management, LLC, filed by

15. NOTABLE10-QQuince Therapeutics, Inc.QNCXAug 14

    Quarterly report

16. ROUTINESCHEDULE 13GQuince Therapeutics, Inc.QNCXAug 14

    Ownership stake disclosure by Cormorant Asset Management, LP

    Cormorant Asset Management, LP, filed by

17. ROUTINE8-KQuince Therapeutics, Inc.QNCXAug 14

    Current report

18. ROUTINESCHEDULE 13GQuince Therapeutics, Inc.QNCXAug 14

    Ownership stake disclosure by BALYASNY ASSET MANAGEMENT L.P.

    BALYASNY ASSET MANAGEMENT L.P., filed by

19. ROUTINES-3/AQuince Therapeutics, Inc.QNCXAug 5

    Securities offering (amended)

20. ROUTINESCHEDULE 13GQuince Therapeutics, Inc.QNCXAug 4

    Ownership stake disclosure by Squadron Capital Management LLC

    Squadron Capital Management LLC, filed by

21. ROUTINE8-KQuince Therapeutics, Inc.QNCXJul 31

    Current report

22. ROUTINEPRE 14AQuince Therapeutics, Inc.QNCXJul 31

    Preliminary proxy statement

23. ROUTINES-3Quince Therapeutics, Inc.QNCXJul 31

    Securities offering

24. ROUTINE8-K/AQuince Therapeutics, Inc.QNCXJul 30

    Current report (amended)

25. ROUTINE8-K/AQuince Therapeutics, Inc.QNCXJun 26

    Current report (amended)

26. ROUTINE8-KQuince Therapeutics, Inc.QNCXJun 26

    Current report

27. ROUTINE4Quince Therapeutics, Inc.QNCXJun 15

    2 insider filings

    David Lamond, insider filing for QNCX

    Show all 2

    • 4Insider filing for QNCXJun 15
    • 4Insider filing for QNCXJun 15

    David Lamond, reporting

28. ROUTINE4Quince Therapeutics, Inc.QNCXJun 11

    2 insider filings

    Brigette Roberts, insider filing for QNCX

    Show all 2

    • 4Insider filing for QNCXJun 11
    • 3New insider at QNCXJun 11

    Brigette Roberts, reporting

29. ROUTINE8-KQuince Therapeutics, Inc.QNCXJun 11

    Current report

30. ROUTINEDQuince Therapeutics, Inc.QNCXJun 11

    2 Form D filings

    Private placement notice

    Show all 2

    • DPrivate placement noticeJun 11
    • DPrivate placement noticeJun 11
31. ROUTINESCHEDULE 13GQuince Therapeutics, Inc.QNCXJun 10

    Ownership stake disclosure by INTEGRATED CORE STRATEGIES (US) LLC

    INTEGRATED CORE STRATEGIES (US) LLC, filed by

32. ROUTINE8-KQuince Therapeutics, Inc.QNCXMay 21

    Current report

33. ROUTINE8-K/AQuince Therapeutics, Inc.QNCXMay 18

    Current report (amended)

34. ROUTINE8-KQuince Therapeutics, Inc.QNCXMay 18

    Current report

35. ROUTINESCHEDULE 13G/AQuince Therapeutics, Inc.QNCXMay 15

    Ownership stake disclosure by Nantahala Capital Management, LLC (amended)

    Nantahala Capital Management, LLC, filed by

36. NOTABLE10-QQuince Therapeutics, Inc.QNCXMay 11

    Quarterly report

37. ROUTINE8-KQuince Therapeutics, Inc.QNCXApr 28

    Current report

38. ROUTINEARSQuince Therapeutics, Inc.QNCXApr 27

    Annual report to shareholders

39. ROUTINEDEFA14AQuince Therapeutics, Inc.QNCXApr 27

    Additional proxy materials

40. ROUTINEDEF 14AQuince Therapeutics, Inc.QNCXApr 27

    Proxy statement

41. ROUTINE8-KQuince Therapeutics, Inc.QNCXApr 22

    Current report

42. ROUTINEPRE 14AQuince Therapeutics, Inc.QNCXApr 17

    Preliminary proxy statement

43. ROUTINES-8Quince Therapeutics, Inc.QNCXApr 17

    Employee stock plan registration

44. NOTABLE10-KQuince Therapeutics, Inc.QNCXApr 10

    Annual report

45. ROUTINE8-KQuince Therapeutics, Inc.QNCXApr 9

    Current report

46. NOTABLENT 10-KQuince Therapeutics, Inc.QNCXApr 1

    Late annual report notice

Older filings on EDGAR